Grant: Undergraduate Student Research Awards (USRA)
University of British Columbia
$6,000.00
Tolerizing mRNA lipid nanoparticles and islet replacement combination therapy for type 1 diabetes
EF 2026-27
Résumé
"Lipid nanoparticles (LNPs) are safe and effective drug delivery vehicles that can be engineered to carry mRNA or small molecules. With an industry partner, the sponsor's lab developed an LNP that combines mRNA-encoding peptide antigens along with immune-modulating small molecules. These tolerizing, antigen-specific LNP (tLNP) attenuate autoimmune (type 1) diabetes (T1D) in mice, preventing disease. To advance tLNPs towards T1D therapy, the Student (TS) will determine whether tLNPs can also prevent rejection of transplanted, insulin-producing, pancreatic islet beta cells in a T1D preclinical model.
Objective. Determine whether tolerizing mRNA LNP can prevent recurrent autoimmunity.
TS will join a team testing tLNPs in combination with pancreatic islet transplants to achieve long-term diabetes reversal. In an ongoing study, diabetic (NOD) mice are stabilized with a slow-release insulin pellet for ~2 wks, then treated with tLNP or control. They are transplanted with islets from genetically identical, immune-deficient (NOD.scid) donor mice. The team hypothesizes that tLNPs will protect transplanted islets and maintain normal glucose control, whereas control mice will lose their islet grafts due to recurrent autoimmunity. TS will analyze grafted islet tissue from mice by immunostaining for immune cell infiltration (CD45), beta cells (insulin), and regulatory T cells (FoxP3), and use image analysis to compare beta cell survival and immune infiltration between groups.
This work will help determine whether combining immune tolerance therapy and beta cell replacement could lead to a lasting treatment for people with long-standing T1D."
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
571668
Name
Pokou Lori-Ann
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Tolerizing mRNA lipid nanoparticles and islet replacement combination therapy for type 1 diabetes
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Drug Delivery Vehicle; Lipid Nanoparticles; Mrna; Peptide Antigens
Abstract
"Lipid nanoparticles (LNPs) are safe and effective drug delivery vehicles that can be engineered to carry mRNA or small molecules. With an industry partner, the sponsor's lab developed an LNP that combines mRNA-encoding peptide antigens along with immune-modulating small molecules. These tolerizing, antigen-specific LNP (tLNP) attenuate autoimmune (type 1) diabetes (T1D) in mice, preventing disease. To advance tLNPs towards T1D therapy, the Student (TS) will determine whether tLNPs can also prevent rejection of transplanted, insulin-producing, pancreatic islet beta cells in a T1D preclinical model.
Objective. Determine whether tolerizing mRNA LNP can prevent recurrent autoimmunity.
TS will join a team testing tLNPs in combination with pancreatic islet transplants to achieve long-term diabetes reversal. In an ongoing study, diabetic (NOD) mice are stabilized with a slow-release insulin pellet for ~2 wks, then treated with tLNP or control. They are transplanted with islets from genetically identical, immune-deficient (NOD.scid) donor mice. The team hypothesizes that tLNPs will protect transplanted islets and maintain normal glucose control, whereas control mice will lose their islet grafts due to recurrent autoimmunity. TS will analyze grafted islet tissue from mice by immunostaining for immune cell infiltration (CD45), beta cells (insulin), and regulatory T cells (FoxP3), and use image analysis to compare beta cell survival and immune infiltration between groups.
This work will help determine whether combining immune tolerance therapy and beta cell replacement could lead to a lasting treatment for people with long-standing T1D."
Competitiondate
202605
Approvedterm2
0 yr 4 mths
Pinamesdelim
Pokou, Lori-Ann
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~